Study of the Phytochemistry and Anticancer Activity of Plants from Family Rubiaceae

What is it about?

This comprehensive review (1995–2024) systematically evaluates medicinal plants from the family Rubiaceae as promising sources for novel anti-cancer therapies, addressing the severe side effects associated with synthetic chemotherapeutic agents. Synthesizing data across major academic databases, the study highlights that Rubiaceae species are rich in diverse bioactive secondary metabolites—including alkaloids, flavonoids, polyphenols, triterpenes, saponins, tannins, and quinones—which demonstrate potent anti-tumor properties such as cytotoxicity, apoptosis induction, antiproliferation, cytostasis, antimetastatic effects, angiogenesis inhibition, and cell cycle arrest. Ultimately, the review establishes a foundational repository for drug discovery, emphasizing the need for future in vivo and clinical trials to confirm the therapeutic efficacy and safety profiles of these botanical compounds.

Featured Image

Photo by Ayush Kumar on Unsplash

Photo by Ayush Kumar on Unsplash

Why is it important?

This article is of vital importance because it bridges traditional phytomedicine and modern oncology by systematically synthesizing 30 years (1995–2024) of literature to highlight the Rubiaceae family as a rich source of less toxic, natural anti-cancer therapies that can mitigate the severe side effects of conventional synthetic drugs. By mapping out specific bioactive phytochemicals—such as alkaloids, flavonoids, polyphenols, and triterpenes—alongside their precise multi-target mechanisms (including apoptosis, cell cycle arrest, and angiogenesis inhibition), the review provides a comprehensive molecular repository that serves as an essential roadmap to accelerate drug discovery and guide future in vivo and clinical trials.

Perspectives